{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-073950","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.236998+00:00","generated_at":"2026-05-21T01:47:50.560864+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"Iterum extends $20M Pfizer milestone payment to Oct 2029; interest rises to 10%","bullets":["$20M regulatory milestone due Oct 2026 extended to Oct 2029 via amended promissory note.","Interest rate increases from 8% to 10%, compounded daily, starting Oct 26, 2026.","ITIL pays Pfizer a transaction fee plus legal expenses; no senior debt or liens without Pfizer consent.","CEO says extension allows capital to be invested in ORLYNVAH launch and geographic expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-073950","json":"https://secwatch.observer/filing/0000950170-25-073950.json","markdown":"https://secwatch.observer/filing/0000950170-25-073950.md","text":"https://secwatch.observer/filing/0000950170-25-073950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025073950/0000950170-25-073950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025073950/itrm-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:47:50.560864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}